Additionally, a trial of 600 mg (on days 1 and 15) of inebilizumab, the CD19 mAb, in combination with 20 mg of prednisone for 14 days followed by a 7 day taper vs. placebo demonstrated significant efficacy in NMO patients (93% with AQP4 antibodies); in 197 days of follow-up, 21 of 174 (12%) treated patients relapsed vs. 22 of 56 (39%) in the placebo group [136]. The gene discussed is CD19; the disease is neuromyelitis optica.